La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Affimed a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Affimed..

Affimed (NASDAQ:AFMD) Azioni, Catena delle Opzioni

Affimed

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.

Affimed NV

Cantor Fitzgerald analyst Li Watsek reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Overweight.

News

Reiteration

Analyst Ratings

AFMD

Cantor Fitzgerald Reiterates Overweight on Affimed

Stifel analyst Bradley Canino maintains Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Hold and lowers the price target from $5 to $4.

Price Target

Stifel Maintains Hold on Affimed, Lowers Price Target to $4

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and maintains $10 price target.

HC Wainwright & Co. Reiterates Buy on Affimed, Maintains $10 Price Target

Biotech

Earnings

Guidance

Health Care

General

Affimed Cash, Cash Equivalents And Investments Of €24.1M Is Expected To Provide Cash Runway Into Q4 2025

Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.91) by 3.3 percent. The company reported quarterly sales of $155.00 thousand which missed the analyst consensus estimate of $2.00 million by 92.25 percent. This is a 92.10 percent decrease over sales of $1.96 million the same period last year.

Affimed Q3 2024 GAAP EPS €(0.94) Misses €(0.91) Estimate, Sales €155.00K Miss €2.00M Estimate

AGAE

AIRI

AKYA

AMAT

AQMS

AREC

ASND

ASTS

AZUL

BENF

BILI

BIOR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BKTI

BKYI

BLUE

BNAI

BNZI

BRAG

BTAI

CASI

CELC

CINT

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CNVS

CRIS

CWCO

DARE

DBGI

DESP

DFLI

DLPN

DMRC

DNMR

DPRO

DTST

EAST

EFXT

ELUT

EWCZ

FLNT

FTLF

GAMB

GAME

GCTS

GDEV

GLOB

HYLN

IMCC

INKT

INTR

ITRM

IVVD

IZEA

LCTX

LIQT

LOCL

LUNR

MITQ

MOVE

MSGM

MUFG

NICE

NOMD

NTES

OCFT

OCUL

OKLO

ONEW

ORGN

PDSB

PHGE

POCI

POST

Earnings Scheduled For November 14, 2024

Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) will release its quarterly earnings report on Thursday, 2024-11-14. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Affimed to report an earnings per share (EPS) of $-1.05.
The market awaits Affimed's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.11, leading to a 0.79% drop in the share price the following trading session.
Here's a look at Affimed's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.980</td>
<td>-1.540</td>
<td>-1.67</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.087</td>
<td>-1.379</td>
<td>-1.50</td>
<td>-1.7</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>20.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731506561_0.png" alt="eps graph" />
<h3>Tracking Affimed's Stock Performance</h3>
Shares of Affimed were trading at $3.76 as of November 11. Over the last 52-week period, shares are up 1.62%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/AFMD/earnings">To track all earnings releases for Affimed visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Affimed's Earnings Forecast

Offerings

Affimed N.V. Files For Mixed Shelf Offering Of Up To $20M

As Of June 30, 2024, Affimed's Cash, Cash Equivalents And Investments Were €34.4M. Based On Operating And Financial Plans Cash-runway Projected Into H2 2025.

Affimed Q2 2024 GAAP EPS €(1.01) Misses €(0.96) Estimate, Sales €154.000K Compared To €1.39M YoY

Management

Affimed Appoints Shawn M. Leland As Chief Executive Officer

Laidlaw &amp; Co. analyst Yale Jen maintains Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) with a Buy and raises the price target from $15 to $25.

Laidlaw & Co. Maintains Buy on Affimed, Raises Price Target to $25

Affimed Anticipates Cash, Equivalents And Short-Term Investments To Support Operations Into H2 2025

Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) reported quarterly losses of $(1.38) per share which beat the analyst consensus estimate of $(1.54) by 10.44 percent. This is a 37.3 percent increase over losses of $(2.20) per share from the same period last year. The company reported quarterly sales of $168.34 thousand which missed the analyst consensus estimate of $1.34 million by 87.44 percent.&nbsp;

Affimed Q1 EPS $(1.38) Beats $(1.54) Estimate, Sales $168.34K Miss $1.34M Estimate

Affimed N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) shares are trading higher on Monday. On Saturday, the company announced longer follow-up data from the&nbsp;EGFRwt cohort and initial clinical efficacy data from the&nbsp;EGFRmut cohort from the ongoing AFM24-102 study in non-small <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39125428/affimed-provides-follow-up-data-of-afm24-plus-atezolizumab-showing-durable-responses-in-heavily-pr" rel="noreferrer noopener">cell lung cancer&nbsp;(NSCLC)</a>.
As of the updated data cutoff on May 13, for the 17&nbsp;EGFRwt patients previously reported, 15 patients were response-evaluable.
Four confirmed objective responses were seen: 1 complete response (CR) and three partial responses (PR).
In addition, eight patients achieved stable disease (SD), resulting in a disease control rate of 71%.
Median progression-free survival was 5.9 months, with a median follow-up of 7.4 months.
3 of 4 responses were ongoing for more than seven months.
All responders were resistant to checkpoint inhibitor treatment before the study, which supports the hypothesis that combining AFM24 with atezolizumab may provide an alternative strategy to overcome resistance to existing therapies.
As of May 21, 2024, 21 heavily pretreated&nbsp;EGFRmut patients had received the combination therapy, of which 13 were response-evaluable.
The combination of AFM24 with atezolizumab showed encouraging signals of clinical activity, including 1 CR, 3 PRs, and six patients with stable disease (SD).
As of the data cutoff, all responses were ongoing. The data suggests that the combination of AFM24 and atezolizumab could be acting synergistically to improve efficacy outcomes.
AFM24 and atezolizumab combination therapy demonstrated a manageable safety profile. The most frequent side effects observed were mild to moderate infusion-related reactions and transient mild to moderate increase in liver enzymes.
The&nbsp;study&#8217;s EGFRwt NSCLC cohort will enroll up to 40 patients, and the&nbsp;EGFRmut NSCLC cohort will enroll up to 25 patients.
Recruitment in both cohorts is ongoing, and further updates are expected in H2 2024.
Price Action: AFMD shares are up 81.4% at $7.89 at last check Monday.
Photo by Aunt Spray via Shutterstock

Movers

Why Is German Biotech Affimed Stock Soaring On Monday?

Shares of Science Applications International Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) declined 11% to $119.91 following <a href="https://www.benzinga.com/news/earnings/24/06/39136938/science-applications-international-optimistic-about-hitting-annual-outlook-despite-q1-revenue-dip-s">first-quarter results.</a>
SAIC reported a 9% revenue decline year over year in the fiscal first quarter of 2025 to $1.847 billion, marginally beating the analyst consensus estimate of $1.844 billion. Adjusted EPS of $1.92 was in line with the analyst consensus estimate, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
SAIC shares dipped 11% to $119.91 on Monday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Microbot Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) jumped 92.5% to $1.9301 after the company received FDA approval to proceed with its pivotal human clinical trial.</li>
<li>Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares jumped 75% to $3.62. Bio-Path presented interim results from Phase 2 study of Prexigebersen (BP1001) in combination with decitabine and venetoclax for acute myeloid leukemia at the American Society Of Clinical Oncology Annual Meeting.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) shares climbed 34.5% to $31.13 after Roaring Kitty on a Reddit post, shared his position on the stock.</li>
<li>Professional Diversity Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPDN#NASDAQ">IPDN</a>) gained 28.5% to $0.65. Professional Diversity Network recently named Megan Bozzuto as interim CFO.</li>
<li>MarineMax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HZO#NYSE">HZO</a>) gained 27% to $36.16. OneWater Marine Inc. is reportedly said to be in advanced discussions to acquire MarineMax.</li>
<li>Crown ElectroKinetics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRKN#NASDAQ">CRKN</a>) shares rose 27% to $0.1271 after dipping 12% on Friday.</li>
<li>MingZhu Logistics Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YGMZ#NASDAQ">YGMZ</a>) climbed 26.5% to $0.4425 after the company reported an agreement to acquire Oxylus Global.</li>
<li>Dogness (International) Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) gained 23.5% to $13.65</li>
<li>Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) gained 22.2% to $5.25 as the company issued follow-up data of AFM24 plus atezolizumab showing durable responses in heavily pretreated NSCLC EGFR wild-type patients and positive initial data from the NSCLC EGFR mutant cohort.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) rose 17.6% to $0.5883.</li>
<li>MacroGenics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) rose 17.5% to $4.8001.</li>
<li>Personalis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) gained 17.5% to $1.5282.</li>
<li>Liquidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQDA#NASDAQ">LQDA</a>) gained 16.8% to $15.03 as the company said District Court issued favorable ruling and denied United Therapeutics&#8217; request to block YUTREPIA&#x2122; launch.</li>
<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) rose 15.5% to $11.18.</li>
<li>Stericycle, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRCL#NASDAQ">SRCL</a>) gained 15% to $59.28 after the company announced that it entered into a definitive agreement to be acquired by Waste Management.</li>
<li>Precigen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) rose 15% to $1.61 after reporting study data for PRGN-2012 for recurrent respiratory papillomatosis patients.</li>
<li>Coherent Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NASDAQ">COHR</a>) gained 13.4% to $64.71 after the company announced the appointment of Jim Anderson as CEO.</li>
<li>CG Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGON#NASDAQ">CGON</a>) rose 11.8% to $36.34</li>
<li>Structure Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPCR#NASDAQ">GPCR</a>) rose 11.8% to $38.25 after the company reported 12-week results for obesity drug GSBR-1290, achieving significant weight loss.</li>
<li>AMC Entertainment Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) gained 11.6% to $4.8330. The resumption of the meme rally came on the back of Keith Gill, also known as "Roaring Kitty," disclosing a substantial position in GameStop on the r/Superstonk Reddit forum.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) gained 10.7% to $16.65.</li>
<li>Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) rose 9% to $21.67 as the company agreed to sell its wholly owned subsidiaries OneNeck IT Solutions and OneNeck Data Center to US Signal Company, LLC.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) shares gained 8.8% to $0.6348 after gaining over 3% on Friday. </li>
<li>Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) gained 8.3% to $218.39 after the company issued preliminary results and said there will be no restatement or adjustment of any audited or unaudited financial statements.</li>
<li>Molecular Partners AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares climbed 8.2% to $4.0699. Molecular Partners presented data from completed Phase 1 trial of MP0317 monotherapy in advanced solid tumors at ASCO 2024.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>CalAmp Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) shares fell 61.4% to $1.03 after the company said it has entered into a Restructuring Support Agreement with its principal secured lender, Lynrock Lake Master Fund LP, who will become the principal equity owner of CalAmp and take the Company private.</li>
<li>Ault Disruptive Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADRT#NASDAQ">ADRT</a>) fell 52.2% to $21.50.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) fell 32.3% to $0.1463. CNS Pharmaceuticals announced a 1-for-50 reverse stock split.</li>
<li>Galera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) fell 30% to $0.1536. Galera Therapeutics will be delisted by Nasdaq.</li>
<li>Portage Biotech Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares fell 29.7% to $0.3365 after gaining over 91% on Friday.</li>
<li>1847 Holdings LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFSH#NYSE">EFSH</a>) dipped 29.5% to $0.7895.</li>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) fell 26.3% to $0.3501.</li>
<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) shares declined 24.4% to $0.3251.</li>
<li>Webuy Global Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBUY#NASDAQ">WBUY</a>) fell 23.7% to $0.1870.</li>
<li>Direct Digital Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) fell 21.2% to $2.67.</li>
<li>Vintage Wine Estates, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWE#NASDAQ">VWE</a>) fell 19.2% to $0.2883.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) fell 19.2% to $105.00</li>
<li>Brand Engagement Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) shares fell 16.4% to $4.55 after jumping over 110% on Friday.</li>
<li>Lattice Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) fell 15.1% to $63.00 after the company announced an interim CEO following Jim Anderson&#8217;s decision to step down as President, CEO and Board member to pursue an opportunity with another company.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) dipped 13.8% to $112.00.</li>
<li>Digital Health Acquisition Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAC#NASDAQ">DHAC</a>) shares fell 10.3% to $15.25 after gaining 13% on Friday.</li>
<li>Grupo Aeroportuario del Centro Norte, S.A.B. de C.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMAB#NASDAQ">OMAB</a>) declined 10.2% to $73.44.</li>
<li>Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) fell 10.1% to $44.05.</li>
<li>Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAC#NYSE">PAC</a>) fell 10% to $169.23.</li>
<li>GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) fell 8.7% to $40.87 after the company said it will appeal a ruling made by the Delaware State Court regarding its ongoing ranitidine litigation.</li>
<li>The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) declined 7.7% to $64.33.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) fell 7.7% to $20.81.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell 7.1% to $129.63. On May 30, Dell reported upbeat earnings and sales results for the first quarter.</li>
<li>Vistra Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) dipped 6.5% to $92.61.</li>
</ul>
The Boston Beer Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAM#NYSE">SAM</a>) shares fell 4.7% to $299.07. Boston Beer shares jumped around 22% on Friday following a report suggesting the company is in talks to sell itself to Suntory. Boston Beer later issued a statement on the company sale speculation. "We are fully focused on our business as an independent company and our return to growth," the company said.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/06/39137769/this-mongodb-analyst-is-no-longer-bearish-here-are-top-5-upgrades-for-monday">This MongoDB Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday</a>

Intraday Update

Markets

Trading Ideas

ADRT

ADSK

BPTH

CAMP

CGON

CNSP

COHR

CRKN

DELL

DHAC

DOGZ

DRCT

EFSH

FFIE

FOXO

GPCR

GRTX

IMCR

IPDN

ISPC

LQDA

LSCC

MBOT

MGNX

MOLN

NVAX

OLMA

Grupo Aeroportuario del Centro NorteB de CV

OMAB

PGEN

PRTG

PSNL

SAIC

SRCL

Vintage Wine Estates, Inc. - Common Stock

WBUY

YGMZ

Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) shares are trading higher Monday after the company announced additional follow-up data from the on-going AFM24-102 study in <a href="https://www.benzinga.com/pressreleases/24/06/g39125428/affimed-provides-follow-up-data-of-afm24-plus-atezolizumab-showing-durable-responses-in-heavily-pr">non-small cell lung cancer (NSCLC).</a>
The Details:
Affimed said in 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved four objective responses, three of four responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 months.
&#8220;The efficacy of the combination of AFM24 and atezolizumab in these heavily pretreated NSCLC patients is encouraging and supports our hypothesis of a synergistic activity of AFM24 with PD-1/PD-L1 blockade. We believe the durability of the responses in EGFRwt tumors is remarkable and is unlikely driven by PD-1/PD-L1 blockade alone, as all patients with responses had documented progression on their previous PD-1/PD-L1 therapy,&#8221; said Dr. Andreas Harstrick, CEO of Affimed.&nbsp;
HC Wainwright &amp; Co. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">reiterated</a> its Buy rating on Affimed and maintained a $10 price target on Monday.&nbsp;
According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affimed shares are trading above the stock&#8217;s 50-day moving average of $5.31 and nearly the stock's entire float of 14.313 million shares has already changed hands in the session.&nbsp;
Related News: <a href="https://www.benzinga.com/news/24/05/39117783/whats-going-on-with-snowflake-stock">What&#8217;s Going On With Snowflake Stock?</a>
<h2 class="wp-block-heading">Should I Sell My AFMD Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Affimed have decreased by 17.48% in the past year. An investor who bought shares of Affimed at the beginning of the year would take a loss of $0.02 per share if they sold it today. The stock has risen 13.48% over the past month, meaning an investor who bought shares on May 1 would see a capital gain of $0.93.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Affimed stock currently has an RSI of 34.92, indicating neutral conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a> 
AFMD Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Affimed shares are up 46.9% at $6.39 at the time of publication Monday.
Image: Mohamed Hassan from Pixabay

Why Affimed Shares Are Soaring

Affimed Q3 2024 Earnings Preview

Here's the major earnings before the open tomorrow

Affimed GAAP EPS of -€0.94, revenue of €0.16M

Affimed (AFMD) has released an update. Affimed N.V. reported increased losses for the third quarter of 2024, with a comprehensive loss of €15.1 mil...

Affimed Faces Growing Losses Amid Financial Struggles

Affimed N.V. 2024 Q3 - Results - Earnings Call Presentation

Affimed N.V. (AFMD) Q3 2024 Earnings Call Transcript

Affimed Therapeutics ( ($AFMD) ) has released its Q3 earnings. Here is a breakdown of the information Affimed Therapeutics presented to its investo...

Affimed Reports Q3 2024 Financial Results and Updates

Analyst Swayampakula Ramakanth of H.C. Wainwright maintained a Buy rating on Affimed (AFMD – Research Report), retaining the price target of $10.00...

Promising Clinical Developments and Data Catalysts Position Affimed for Strong Future Prospects

Stifel lowered the firm's price target on Affimed (AFMD) to $4 from $5 and keeps a Hold rating on the shares after the company provided granularity...

Affimed price target lowered to $4 from $5 at Stifel

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on AFMD stock, giving a Buy rating on November 15. Daina Graybosch's r...

Affimed's Innate Cell Engagers' Upcoming Clinical Updates Poised to Capture Investor Interest Amidst Durability Concerns

CVSI

DTEGY

EONGY

KEYUF

KNTNF

MKGAF

NLCP

PAVM

POLA

PVCT

QBTS

SACH

SIEGY

SPCB

VEON

VISL

WKHS

XNET

Press Releases

MAIA Biotechnology (MAIA) to Showcase Groundbreaking Telomere-Targeting Cancer Treatments at BIO International Convention 2024

Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024

Affimed Reports First Quarter 2024 Financial Results & Business Update

Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024

Affimed Appoints Shawn M. Leland as Chief Executive Officer

Comments

Affimed

Affimed (AFMD) Opzioni

Affimed (NASDAQ:AFMD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO